ADAORA NNANNA: Open Payments
NPI 1396294161 · BOWIE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$654 in 30 payments from 10 companies in 2025. Trend: 2023 $689 · 2024 $992 · 2025 $654
Food & beverage: $654
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 7 | $166 |
| Neurocrine BioSciences, Inc. | 5 | $133 |
| Vanda Pharmaceuticals Inc. | 4 | $102 |
| Tris Pharma Inc | 6 | $98 |
| Corium, LLC | 2 | $45 |
| Supernus Pharmaceuticals, Inc. | 2 | $29 |
| Teva Pharmaceuticals USA, Inc. | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| E.R. Squibb & Sons, L.L.C. | 1 | $20 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
Products named: VRAYLAR, INGREZZA, Dyanavel XR, HETLIOZ, Azstarys, Qelbree, AUSTEDO XR, FANAPT.
Industry payments across MD — which companies pay providers there.
